Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

CNS Pharmaceuticals shares are trading higher by 76% Wednesday morning. The stock faces potential delisting for not meeting ...

As CNS Pharmaceuticals moves forward with its offerings and the continued development of Berubicin, the path ahead will be pivotal. Investors and stakeholders will be watching closely to see how the ...

CNS Pharmaceuticals (CNSP) announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been ...

HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a ...

Ladenburg Thalmann has recently reduced CNS Pharmaceuticals Inc (CNSP) stock to Neutral rating, as announced on December 28, 2020, according to Finviz. Analyst ratings are significant because they ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The company continues to prioritize its pipeline development, with expectations for further advancements in clinical trials for its CNS product candidates. Looking ahead, Supernus Pharmaceuticals aims ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...